Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
502
Travoprost (0.004%) 1 drop each eye once daily
Europe
Fort Worth, Texas, United States
Mean Intraocular Pressure
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
Time frame: At 5 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.